ClinicalTrials.gov record
Completed Phase 4 Interventional

Epidiolex® for Anxiety in Pediatric Epilepsy

ClinicalTrials.gov ID: NCT05324449

Public ClinicalTrials.gov record NCT05324449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy

Study identification

NCT ID
NCT05324449
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Enrollment
20 participants

Conditions and interventions

Interventions

  • Cannabidiol 100 MG/ML Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 4, 2022
Primary completion
Mar 16, 2025
Completion
May 4, 2025
Last update posted
Jul 1, 2025

2022 – 2025

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Kennedy Krieger Institute Baltimore Maryland 21205

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05324449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05324449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →